Apnex Medical Inc.
This article was originally published in Start Up
Apnex Medical is developing a tiny device that it thinks could become an enormous game changer in the bid to better treat obstructive sleep apnea. The technology is similar to a pacemaker in both size and concept. But instead of the heart, the device stimulates the musculature of the upper airway at the base of the tongue - the genioglossus - via the hypoglossal nerve. In obstructive sleep apnea, the muscle doesn't always activate sufficiently, which can lead to a collapsed airway.
You may also be interested in...
The current specialty-dominated care paradigm for sleep apnea can't scale-up to meet the demands of an enormous and serious chronic disease. New companies help move diagnosis and treatment to the physicians that see patients first.
Implantable neurostimulation devices have the potential to ameliorate a number of debilitating conditions in which neural pathways play a role. Combined, these applications are expected to bring in device revenues of nearly $1.4 billion in the US alone in 2010, and that number is forecast to increase by double-digits going forward, reaching over $2.6 billion by 2014, according to Medtech Insight's recently published report, "US Markets for Neurostimulation Products."
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Transdermal Drug Delivery: More Than Skin Deep, features profiles of AllTranz, Ocelus, Quinnova and Syntropharma. Plus these Start-Ups Across Health Care: Apnex Medical, Cellular Dynamics, Helix Therapeutics, Presym and Vatrix Medical.